These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 23219016)

  • 21. Kappa-opioid ligands in the study and treatment of mood disorders.
    Carlezon WA; Béguin C; Knoll AT; Cohen BM
    Pharmacol Ther; 2009 Sep; 123(3):334-43. PubMed ID: 19497337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endogenous opiates and behavior: 2013.
    Bodnar RJ
    Peptides; 2014 Dec; 62():67-136. PubMed ID: 25263178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of kappa-opioid receptor activation in mediating antinociception and addiction.
    Wang YH; Sun JF; Tao YM; Chi ZQ; Liu JG
    Acta Pharmacol Sin; 2010 Sep; 31(9):1065-70. PubMed ID: 20729876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
    Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
    Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opioids in chronic pain.
    Przewłocki R; Przewłocka B
    Eur J Pharmacol; 2001 Oct; 429(1-3):79-91. PubMed ID: 11698029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of the opioid receptors involved in passive-avoidance learning in the day-old chick during the second wave of neuronal activity.
    Freeman FM; Young IG
    Brain Res; 2000 May; 864(2):230-9. PubMed ID: 10802030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of mu- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine.
    Shahbazian A; Heinemann A; Schmidhammer H; Beubler E; Holzer-Petsche U; Holzer P
    Br J Pharmacol; 2002 Feb; 135(3):741-50. PubMed ID: 11834622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endogenous opiates and behavior: 2006.
    Bodnar RJ
    Peptides; 2007 Dec; 28(12):2435-513. PubMed ID: 17949854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain regional Fos expression elicited by the activation of mu- but not delta-opioid receptors of the ventral tegmental area: evidence for an implication of the ventral thalamus in opiate reward.
    David V; Matifas A; Gavello-Baudy S; Decorte L; Kieffer BL; Cazala P
    Neuropsychopharmacology; 2008 Jun; 33(7):1746-59. PubMed ID: 17895918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of mu- and delta-opioid receptors in the nucleus accumbens in cocaine-seeking behavior.
    Simmons D; Self DW
    Neuropsychopharmacology; 2009 Jul; 34(8):1946-57. PubMed ID: 19279569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endogenous opioid systems: current concepts and clinical correlations.
    Benarroch EE
    Neurology; 2012 Aug; 79(8):807-14. PubMed ID: 22915176
    [No Abstract]   [Full Text] [Related]  

  • 32. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
    Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
    Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression.
    Masi G; Brovedani P
    CNS Drugs; 2011 Nov; 25(11):913-31. PubMed ID: 22054117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of dopamine and glutamate on synaptic plasticity: a computational modeling approach for drug abuse as comorbidity in mood disorders.
    Qi Z; Kikuchi S; Tretter F; Voit EO
    Pharmacopsychiatry; 2011 May; 44 Suppl 1():S62-75. PubMed ID: 21544747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The opioid system and the social brain: implications for depression and suicide.
    Lutz PE; Courtet P; Calati R
    J Neurosci Res; 2020 Apr; 98(4):588-600. PubMed ID: 30051488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
    J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opioid system modulation of cognitive affective bias: implications for the treatment of mood disorders.
    Varastehmoradi B; Wegener G; Sanchez C; Smith KL
    Behav Pharmacol; 2020 Apr; 31(2&3):122-135. PubMed ID: 32168024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuronal plasticity: a link between stress and mood disorders.
    Calabrese F; Molteni R; Racagni G; Riva MA
    Psychoneuroendocrinology; 2009 Dec; 34 Suppl 1():S208-16. PubMed ID: 19541429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delta Opioid Receptors and Modulation of Mood and Emotion.
    Dripps IJ; Jutkiewicz EM
    Handb Exp Pharmacol; 2018; 247():179-197. PubMed ID: 28993835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Facilitation of μ-opioid receptor activity by preventing δ-opioid receptor-mediated codegradation.
    He SQ; Zhang ZN; Guan JS; Liu HR; Zhao B; Wang HB; Li Q; Yang H; Luo J; Li ZY; Wang Q; Lu YJ; Bao L; Zhang X
    Neuron; 2011 Jan; 69(1):120-31. PubMed ID: 21220103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.